While traditional drug delivery companies have focused on improving the bioavailability of drugs to increase their concentration in the bloodstream, the final step of gaining entry inside cells has been largely unaddressed by conventional technologies. However, several proteins or peptides recently have been shown to mediate the entry of a variety of compounds (including other proteins) across the cell membrane, a finding that CellGate Inc. hopes to commercialize.

CellGate develops intracellular transport peptides that improve the delivery of biologics and small molecules into cells. "Basically, we can get any molecule into any cell," said President and CEO Thomas Schultz. The company is using its technology to improve existing compounds as well as develop topical formulations of approved drugs.